Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNKD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMannKind wins FDA approval to expand Afrezza inhaled insulin to children ages 6+
Filed June 2, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
FDA approved Afrezza for pediatric use in children and adolescents aged 6+ with type 1 and type 2 diabetes, expanding addressable market to include over 350,000 U.S. pediatric patients previously excluded from the product label.
Item 8.01 verify on EDGAR → -
medium
Approval fulfills the final postmarketing requirement from Afrezza's original 2014 FDA approval, eliminating a 12-year regulatory obligation and associated compliance uncertainty.
Item 8.01 verify on EDGAR →
Summary
MannKind announced FDA approval to market Afrezza, its inhaled insulin product, to children and adolescents aged 6 and older with diabetes. This label expansion opens access to a pediatric market of more than 350,000 patients in the United States who were previously unable to use the product.
The approval also closes out the last outstanding postmarketing study requirement from the drug's initial 2014 approval, removing a longstanding regulatory overhang. For retail investors, this represents a meaningful commercial opportunity. Pediatric diabetes is a growing market, and inhaled insulin may offer advantages over injections for children and families seeking less invasive treatment options.
The key question is adoption: watch for updates on prescriber uptake, payer coverage decisions for pediatric use, and any commercial partnerships MannKind pursues to reach this new patient population. Revenue guidance updates in coming quarters will signal whether the expanded label translates into material sales growth.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 29, 2026, we announced that the U.S. Food and Drug Administration (FDA) approved Afrezza®(insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
The FDA has approved Afrezza, MannKind's inhaled insulin product, for use in children and adolescents aged 6 and older with type 1 or type 2 diabetes. This expands the approved patient population beyond adults to include pediatric patients, opening a market of over 350,000 children and adolescents living with diabetes in the United States.
Added in current filing · verify on EDGAR →
The FDA also stated that the supplemental biologics license application for the pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza as set forth in the original June 27, 2014 approval letter.
The pediatric approval satisfies the final postmarketing requirement imposed when Afrezza was originally approved in 2014. This removes a regulatory obligation that has been outstanding for nearly 12 years and eliminates any associated compliance risk or uncertainty.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify